Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.58 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | MDM4 | O15151 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13044090 | 1.00 | CASP3 (0.58) | CASP3PIN1KMT2AEPHX2MDM4 | |
| SCHEMBL13722468 | 0.91 | CASP3 (0.52) | CASP3PIN1KMT2AEPHX2MDM4 | |
| SCHEMBL29356434 | 0.90 | CASP3 (0.60) | CASP3PIN1KMT2AEPHX2MDM4 | |
| SCHEMBL2591012 | 0.90 | CASP3 (0.58) | CASP3PIN1KMT2AEPHX2MDM4 | |
| SCHEMBL29670320 | 0.90 | CASP3 (0.58) | CASP3PIN1KMT2AEPHX2MDM4 | |
| SCHEMBL31697682 | 0.90 | CASP3 (0.60) | CASP3PIN1KMT2AEPHX2MDM4 | |
| SCHEMBL178791 | 0.90 | CASP3 (0.60) | CASP3PIN1KMT2AEPHX2MDM4 | |
| SCHEMBL799720 | 0.90 | CASP3 (0.60) | CASP3PIN1KMT2AEPHX2MDM4 | |
| SCHEMBL120703 | 0.90 | CASP3 (0.60) | CASP3PIN1KMT2AEPHX2MDM4 | |
| SCHEMBL29375252 | 0.90 | CASP3 (0.60) | CASP3PIN1KMT2AEPHX2MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522194-B2 | Methods of using monomethylvaline compositions having phenylalanine carboxy modifications at the C-terminus | SEATTLE GENETICS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20150044238-A1 | METHODS OF USING MONOMETHYLVALINE COMPOSITIONS HAVING PHENYLALANINE CARBOXY MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2015-02-12 | — | — | US | disclosed |
| US-8906376-B2 | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease | SEATTLE GENETICS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8871720-B2 | Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus | SEATTLE GENETICS, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8343928-B2 | Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus | SEATTLE GENETICS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120034246-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20110112114-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110064753-A1 | DRUG CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE | SEATTLE GENETICS, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| US-7851437-B2 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | SEATTLE GENETICS INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-20100062008-A1 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | SEATTLE GENETICS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | MMAB, PTMS, DNPEP | CASP3 1276/4885PIN1 1129/4885KMT2A 1279/4885 |
| US-20110064753-A1 | DRUG CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE | CD47, CD2, CD22 | CASP3 540/4885PIN1 428/4885KMT2A 649/4885 |
| US-20100062008-A1 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | DAD1, DDOST, STT3A | CASP3 1847/4885PIN1 308/4885KMT2A 3601/4885 |
| US-20120034246-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | CASP3 2155/4885PIN1 486/4885KMT2A 2858/4885 |
| US-20110112114-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE | HPN, PRSS1, PRSS3 | CASP3 401/4885PIN1 851/4885KMT2A 3959/4885 |
| US-20150044238-A1 | METHODS OF USING MONOMETHYLVALINE COMPOSITIONS HAVING PHENYLALANINE CARBOXY MODIFICATIONS AT THE C-TERMINUS | MARS1, PTMS, L3MBTL1 | CASP3 1702/4885PIN1 562/4885KMT2A 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.